SCHEDULE: Lightspeed Venture Partners Discloses 7.6% Stake in Odyssey
Schedule 13G
Lightspeed Venture Partners XV-B (Ignite), L.P. has filed a Schedule 13G reporting a 7.6% beneficial ownership stake in Odyssey Therapeutics, Inc.
Summary
- Lightspeed Venture Partners XV-B (Ignite), L.P. and its associated general partners reported beneficial ownership of 3,608,443 shares of Odyssey Therapeutics, Inc. common stock.
- This holding represents 7.6% of the total outstanding common stock of the issuer.
- The filing confirms the shares were acquired for investment purposes without the intent to change or influence control of the company.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing institutional ownership levels.
Positives
- Significant institutional backing from a prominent venture capital firm, signaling confidence in the company's long-term prospects.
Negatives
- NA
Risks
- Concentration of ownership by institutional investors can lead to increased stock price volatility if the investor decides to divest.
Future Outlook
The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that institutional 13G filings for biotech companies are standard indicators of post-IPO or post-financing stability, reflecting continued support from early-stage venture capital backers.
Comparison to Industry Standards
- The 7.6% ownership stake is consistent with typical venture capital holdings in emerging biotechnology firms following a public offering.
Legal Proceedings
- None disclosed.
Related Party Transactions
- None disclosed.
Stakeholder Impact
- Shareholders may view the continued holding by a major venture firm as a sign of stability.
Next Steps
- The reporting persons will continue to monitor their investment in Odyssey Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 05/07/2026 | Date of the issuer's prospectus. |
| 05/08/2026 | Date the issuer's prospectus was filed with the SEC. |
| 05/11/2026 | Date of the event requiring the filing of this statement. |
| 05/18/2026 | Date of the Schedule 13G filing and signature. |
Keywords
Odyssey Therapeutics, Lightspeed Venture Partners, Schedule 13G, Beneficial Ownership, Biotech, Institutional Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.